CTMX — CytomX Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $687.91m
- $544.28m
- $138.10m
- 48
- 55
- 93
- 73
Annual cashflow statement for CytomX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.9 | -116 | -99.3 | -0.569 | 31.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 17.4 | 16.6 | 16.7 | 4.87 | 6.55 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 18.1 | -22.4 | -30.7 | -62.5 | -126 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 5.26 | -119 | -111 | -56 | -86.2 |
| Capital Expenditures | -2.31 | -1.61 | -1.74 | -0.84 | -0.31 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16.4 | 24.1 | 100 | -150 | 100 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -18.7 | 22.5 | 98.3 | -151 | 99.7 |
| Financing Cash Flow Items | — | — | 0.648 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 16.9 | 110 | 0.648 | 30.2 | 7.52 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.43 | 13.7 | -11.9 | -176 | 21 |